226 related articles for article (PubMed ID: 38095804)
1. Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia.
Larouche M; Khoury E; Brisson D; Gaudet D
Curr Atheroscler Rep; 2023 Dec; 25(12):1101-1111. PubMed ID: 38095804
[TBL] [Abstract][Full Text] [Related]
2. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan DC; Watts GF
Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
[TBL] [Abstract][Full Text] [Related]
3. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia.
Nurmohamed NS; Dallinga-Thie GM; Stroes ESG
Expert Rev Cardiovasc Ther; 2020 Jun; 18(6):355-361. PubMed ID: 32511037
[TBL] [Abstract][Full Text] [Related]
4. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Reeskamp LF; Tromp TR; Stroes ESG
Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
[TBL] [Abstract][Full Text] [Related]
5. New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
Olkkonen VM; Sinisalo J; Jauhiainen M
Atherosclerosis; 2018 May; 272():27-32. PubMed ID: 29544086
[TBL] [Abstract][Full Text] [Related]
6. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
7. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC
Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780
[TBL] [Abstract][Full Text] [Related]
8. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
9. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
10. Updates in Drug Treatment of Severe Hypertriglyceridemia.
Gouni-Berthold I; Schwarz J; Berthold HK
Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic approaches for the treatment of hypertriglyceridemia.
Gouni-Berthold I; Schwarz J
Herz; 2022 Jun; 47(3):220-227. PubMed ID: 35451595
[TBL] [Abstract][Full Text] [Related]
12. Angiopoietin-like 3: An important protein in regulating lipoprotein levels.
Burks KH; Basu D; Goldberg IJ; Stitziel NO
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101688. PubMed ID: 35999139
[TBL] [Abstract][Full Text] [Related]
13. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
[TBL] [Abstract][Full Text] [Related]
14. Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity.
Murawska K; Krintus M; Kuligowska-Prusinska M; Szternel L; Stefanska A; Sypniewska G
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959891
[TBL] [Abstract][Full Text] [Related]
15. Severe hypertriglyceridemia: Existing and emerging therapies.
Malick WA; Do R; Rosenson RS
Pharmacol Ther; 2023 Nov; 251():108544. PubMed ID: 37848164
[TBL] [Abstract][Full Text] [Related]
16. A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward NC; Chan DC; Watts GF
BioDrugs; 2022 Mar; 36(2):121-135. PubMed ID: 35286660
[TBL] [Abstract][Full Text] [Related]
17. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
Quispe R; Sweeney T; Varma B; Agarwala A; Michos ED
Curr Atheroscler Rep; 2022 Oct; 24(10):767-778. PubMed ID: 35895246
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
[TBL] [Abstract][Full Text] [Related]
19. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ
Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717
[TBL] [Abstract][Full Text] [Related]
20. New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3.
Kim JY; Kim NH
J Lipid Atheroscler; 2023 Jan; 12(1):23-36. PubMed ID: 36761060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]